In metastatic breast cancer, upregulation of IL‐25 and IL‐17RB has been observed by Jiang et al. They have emphasized that using blocking anti‐IL‐25 antibodies may provide an innovative approach to treat human breast cancer.42 Here, IL25 is linked to breast carcinoma.